New York, New York--(Newsfile Corp. - February 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline.SO WHAT: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a co ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Intellia Therapeutics reported a narrower loss of 83 cents per share for Q4 2025, compared to a loss of $1.27 per share in the same quarter last year, and better than the Zacks Consensus Estimate of a loss of 99 cents [1][7] - The company generated revenues of $23 million in Q4 2025, significantly exceeding the Zacks Consensus Estimate of $12 million, marking a 73.8% year-over-year increase driven by collaboration revenues [2][7] - Intellia's stock rose by 6.4% following the positive earnings report, with a 24% increase over the past six months, outperforming the industry average of 22.4% [3] Financial Performance - Research and development expenses for Q4 totaled $88.7 million, a decrease of 24.1% from the previous year, attributed to lower employee-related expenses and stock-based compensation [4] - General and administrative expenses increased by 2.2% year-over-year to $33.1 million [4] - For the full year 2025, Intellia reported revenues of $67.7 million, up from $57.9 million in 2024, with a loss of $3.81 per share, an improvement from a loss of $5.25 per share in the prior year [9] Cash Position - As of December 31, 2025, Intellia had cash, cash equivalents, and marketable securities totaling $605.1 million, down from $669.9 million as of September 30, 2025 [5] Pipeline Developments - Intellia is developing lonvo-z for hereditary angioedema (HAE), with top-line data expected by mid-2026 and a potential U.S. launch in the first half of 2027 [7][13] - The FDA lifted the clinical hold on the IND for the phase III study of nexiguran ziclumeran (nex-z), with enrollment expected to complete in the second half of 2026 [11][12] - Intellia is currently working with the FDA to resolve the clinical hold on the MAGNITUDE study for nex-z [12]

Ginkgo Bioworks (NYSE:DNA) shares are down following the company’s fourth-quarter and full-year 2025 financial report.The stock’s decline comes as the company is focusing on investing in autonomous labs.Divests Non-Core Business To Focus On RoboticsFor the fourth quarter of 2025, Ginkgo Bioworks reported a strategic pivot towards robotics and AI, with CEO Jason Kelly emphasizing the company’s collaboration with the Department of Energy and OpenAI.The company also announced plans to divest its biosecurity bu ...

Nuvalent, Inc. (NUVL) closed the last trading session at $103.93, gaining 1.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $142.65 indicates a 37.3% upside potential.The mean estimate comprises 17 short-term price targets with a standard deviation of $13.19. While the lowest estimate of $125.00 indicates a 20.3% increase from the current price level, the most optimistic analyst ...

Core Insights - Kymera Therapeutics (KYMR) reported a wider fourth-quarter 2025 loss of 97 cents per share, exceeding the Zacks Consensus Estimate of a loss of 77 cents, and a deterioration from a loss of 88 cents per share in the same quarter last year [1][7] - The company's collaboration revenues were $2.9 million, significantly below the Zacks Consensus Estimate of $30 million, and down from $7.4 million in the year-ago quarter [2][5] - Kymera's shares have increased by 214.2% over the past year, outperforming the industry average rise of 18.6% [2] Financial Performance - Research and development (R&D) expenses rose to $83.8 million, a 16.7% increase year over year, driven by investments in the STAT6 program and other discovery initiatives [3][14] - General and administrative expenses increased by 3.7% year over year to $16.9 million, influenced by higher legal and professional service fees, as well as increased personnel and facility costs [4] - For the full year 2025, revenues decreased by 16.8% to $39.2 million, missing the Zacks Consensus Estimate of $54.7 million, while loss per share increased to $3.69 from $2.98 in 2024 [5] Capital and Funding - In December 2025, Kymera completed an underwritten equity offering that generated approximately $692 million in gross proceeds, raising year-end cash to about $1.6 billion and extending the cash runway into 2029 [4][14] Pipeline Developments - Kymera is advancing its targeted protein degradation (TPD) strategy, with KT-621 in phase 2 development for atopic dermatitis and asthma, showing promising results in recent studies [8][9] - The BROADEN2 phase IIb study for KT-621 has been expanded to include adolescents, with data expected from mid- to late-2027 [10] - KT-579, an oral IRF5 degrader, has begun phase 1 trials following FDA clearance, with results anticipated in the second half of 2026 [11] - The partnered program KT-485/SAR447971 is expected to enter clinical trials in 2026, while preclinical work continues on an oral CDK2 program with Gilead [12][13] Investment Thesis - The investment thesis focuses on the execution of Kymera's pipeline in targeted protein degradation, particularly the progress of KT-621, which could positively impact stock performance [15]

Key Takeaways DNLI reported a Q4 loss of $0.73 per share, beating estimates but wider year over year.Denali Therapeutics' BLA for tividenofusp alfa faces April 5, 2026, FDA action date after major amendment.DNLI ended 2025 with $966.2M in cash as it advances DNL126 and other partnered programs.Denali Therapeutics (DNLI) reported a fourth-quarter 2025 loss of 73 cents per share, narrower than the Zacks Consensus Estimate of a loss of 75 cents. The company reported a loss of 67 cents in the year-ago quarter.T ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present new data in genitourinary malignancies at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026. Across four oral presentations in muscle-invasive bladder cancer (MIBC), these data reinforce Signatera's role in identifying patients who benefit from adjuvant immunotherapy, supporting. ...

Beam Therapeutics Inc. ( BEAM ) was founded by David Liu, J. Keith Joung, and Feng Zhang in 2017. Its headquarters and research hub are in Cambridge, MA, while its manufacturing hub is in Durham, NC. It is one ofI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believe the key to creating we ...

ALX Oncology (NasdaqGS:ALXO) Q4 2025 Earnings call February 27, 2026 08:30 AM ET Company ParticipantsBarbara Klencke - Chief Medical OfficerHarish Shantharam - CFOJason Lettmann - CEORamakanth Swayampakula - Managing DirectorConference Call ParticipantsAllison Bratzel - Senior Research AnalystDaniel Braun - AnalystRoger Song - Senior Equity Research AnalystSam Slutsky - Senior Research AnalystOperatorGreetings, and welcome to the ALX Oncology fourth quarter 2025 financial results call and webcast. At this t ...